Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P5PD
|
|||
| Former ID |
DIB000367
|
|||
| Drug Name |
IMMU-114
|
|||
| Synonyms |
HLA-DR mAb (cancer), Immunomedics
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Phase 1 | [1] | |
| leukaemia [ICD-11: 2A60-2B33; ICD-9: 208.9] | Phase 1 | [2] | ||
| Company |
Immunomedics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | MHC class II antigen DR (HLA-DR) | Target Info | . | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039238) | |||
| REF 3 | The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD. Bone Marrow Transplant. 2012 Jul;47(7):967-80. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.